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Background: Pulmonary alveolar proteinosis (PAP) is a rare disorder characterised by abundant alveolar
accumulation of surfactant lipoproteins. Serum levels of KL-6, high molecular weight human MUC1 mucin, are
increased in the majority of patients with PAP. The prognostic significance of KL-6 in PAP is still unknown. Aim of
the study was to evaluate whether serum KL-6 levels correlate with the outcome of the disease.
Patients and methods: From 2006 to 2012, we prospectively studied 33 patients with primary autoimmune PAP.
We measured serum KL-6 levels by ELISA (Eisai, Tokyo, Japan), and evaluated the correlation between initial KL-6
levels and clinical variables. Disease progression was defined as deterioration of symptoms, and/or lung function,
and/or chest imaging.
Main results: The initial serum KL-6 levels were significantly correlated with the baseline PaO2, A-aDO2, DLCO, VC
and TLC (p=0.042, 0.012, 0.012, 0.02 and 0.013, respectively). The change over time of serum KL-6 correlated with
the change over time of DLCO (p=0.017). The initial serum KL-6 levels were significantly higher in patients with
disease progression than in those with remission (p<0.001). At a cut-off level of 1526 U/mL, the initial serum KL-6
level predicted disease progression (Se 81%, Sp 94%). At a cut-off level of 2157 U/mL, the initial serum KL-6
predicted the necessity of repeated whole lung lavage (Se 83%, Sp 96%). In the multivariate analysis, the initial
serum level of KL-6 was the strongest predictor of disease progression (HR 9.41, p=0.008).
Conclusions: Serum KL-6 seems to predict outcome in PAP.
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Pulmonary alveolar proteinosis (PAP), first described in
1958 [1], is a rare syndrome characterized by the intra-
alveolar accumulation of surfactant lipids and proteins.
PAP can occur in three distinct clinical forms: hereditary
(caused by mutations in the GM-CSF receptor gene),
primary autoimmune (associated with GM-CSF auto-
antibodies), and secondary to several underlying conditions
(malignancies, toxic agents, immunosuppression) [2-6].
KL-6 is a mucin-like glycoprotein present in the human
MUC1 mucin [7]. The origin of the elevated KL-6 in PAP
has been shown to be the hyperplastic alveolar type II
pneumocyte [8]. After production, KL-6 has been found
to be immunolocalized in the fine granular substance of
the alveoli, in a distribution that is similar to SP-A [9]. It* Correspondence: ulrich.costabel@ruhrlandklinik.uk-essen.de
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reproduction in any medium, provided the orhas been hypothesized that KL-6 is transferred into the
bloodstream via lymphatic vessels [8]. KL-6 concentra-
tions in BAL are 3–5 fold higher than in serum of PAP
patients [10,11].
The role of serum KL-6 as sensitive biomarker for various
interstitial lung diseases has been demonstrated in idio-
pathic pulmonary fibrosis, radiation pneumonitis, drug-
induced pneumonitis, hypersensitivity pneumonitis, CTD-
associated ILD, pulmonary sarcoidosis, and cystic fibrosis
[12-15]. Serial changes of serum KL-6 predict the short-
term prognosis in rapidly progressive IPF [16], and initial
serum KL-6 levels are associated with long-term survival
in IPF and pulmonary fibrosis in connective-tissue disease
[17-21].
The clinical utility of serum KL-6 in PAP has been
only partially investigated [10,22-25]. The aim of the
present study was to evaluate the prognostic utility of
serum KL-6 level in a relevant cohort of PAP patients.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported in the form of an abstract [26].
Patients and methods
Disposition of the patients
We prospectively studied 33 Caucasian PAP patients be-
tween 2008 and 2012. The study was approved by the
local IRB (approval number 06–3170). Informed consent
was obtained from the patients.
Diagnosis of PAP
The diagnosis of PAP was based on diagnostic BAL find-
ings, characteristic HRCT, and/or histopathologic findings
on biopsy [4,27]. All the patients had the primary auto-
immune form: GM-CSF autoantibodies were detected in
all patients (Table 1).
Definition of disease progression, improvement and
remission
Disease progression was defined as deterioration of symp-
toms (worsening of dyspnea, cough, chest pain and weight
loss), and/or lung function (decrease in forced vital cap-
acity >10%), and/or chest imaging (increase of the previ-
ous findings or appearance of new infiltrates characteristic
of PAP) since the last follow-up visit. In order to avoid the
bias of subjective interpretation in the assessment of
disease progression, we included in this group with
disease progression only the patients who requiredTable 1 Baseline demographics and patients’ characteristics o
outcome (all data collected at baseline)
All patients
N=33
Gender (M/F) N(%) 18/15 (54/46)
Age (yrs) 49±12 (19–79)
Smoking habits (never/ex/current) N(%) 5/12/16 (15/36/49)
BMI (kg/m2) 26±5 (19–36)
PaO2 (mmHg) 72±15 (47–117)
A-aDO2 (mmHg) 37±14 (11–63)
VC (% pred) 80±16 (44–123)
FEV1 (% pred) 75±16 (43–104)
TLC (% pred) 79±17 (42–116)
DLCO (% pred) 57±19 (21–96)
GM-CSF autoantibody (μg/mL) § 48±22
KL-6 (U/mL) 2049±1893
LDH (IU/L) § 283±93 (140–522)
CEA (ng/mL) § 8.5±7 (1–27)
Unless otherwise indicated, values are expressed as mean ± SD (range).
n.s.= not significant.
* patients who improved or remained stable and did not receive WLL within 18 mo
§ the cut-off of normality for each biomarker is reported in the methods.
† Fisher's exact test, for all other comparisons in the table Student's t-test was usedtreatment with whole lung lavage (WLL) in the follow-
up period. In our centre, PAP patients should be
submitted to WLL (1) in presence of persistent (PaO2
<70 mmHg with no change for at least 3 months) or
progressive respiratory failure (decrease in PaO2 >10
mmHg from the last follow up visit, or necessity of
oxygen treatment in the last 3 months); (2) in the ab-
sence of respiratory difficulty at rest, the presence of
exercise desaturation (decrease in PaO2 >10 mmHg or
SaO2 >5%).
We defined a patient as improved if PAP symptoms
(dyspnea, cough, chest pain and weight loss) ameliorated
or disappeared and lung function tests improved (forced
vital capacity >5% and/or DLCO >10% and/or PaO2 >
10 mmHg since the last measurement), and chest im-
aging showed stability or amelioration of the previous
findings.
A stable course of disease was defined as absence of
new PAP symptoms or no worsening of the previous
symptoms (see above), no change in lung function tests
and no new radiological infiltrates. We considered a
patient as stabilized if the disease course changed from
progressive to stable (see the definition above) after
treatment or spontaneously.
A patient was defined as being in remission, if he/she im-
proved or remained stable and did not receive WLL within
18 months prior to the last evaluation. The 18 months
limit is based on longterm experience in our centre.f all patients and of subgroups according to disease
Outcome
Remission Progression p















nths prior to the last evaluation.
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Figure 1 Initial KL-6 serum levels and disease outcome. The
graph shows the initial KL-6 serum concentrations in patients having
progression or remission of disease during the follow-up. Dots
represent single patients. Grid line represents the upper limit of
normal (<458 U/mL). Bold lines represent the mean value.
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Serum samples were obtained by venipuncture at time
of first evaluation and then every 202±148 days, and
were stored at −20 or −80°C until analysis.
Serum KL-6 was measured by ELISA (Eisai Co. Ltd.,
Tokyo, Japan) as described before [10] (upper limit of
normal <458 U/mL as determined in 142 Caucasian
healthy subjects).
GM-CSF autoantibody concentration was measured by
ELISA as previously reported [28-30]. GM-CSF values
<10 μg/mL are to be considered as normal [31].
CEA and LDH were routinely measured in serum (nor-
mal value for CEA <2.5 ng/mL and for LDH <225 IU/L).
Pulmonary function tests
Measurements including vital capacity (VC), forced ex-
piratory volume in one second (FEV1), total lung cap-
acity (TLC), diffusing capacity of the lung for carbon
monoxide (DLCO), partial pressure of oxygen in arterial
blood (PaO2), and alveolar-arterial oxygen gradient
(A-aDO2) were performed along with the blood sam-
ple collection. Values were expressed as percentages of
predicted normal values [32].
Statistics
Continuous variables were evaluated for a normal distri-
bution with the Kolmogorov-Smirnov test. Parametric
data are presented as mean ± SE and nonparametric data
are presented as median and interquartile range (IQR).
Categorical variables are presented as either a percentage
of the total or numerically, as appropriate. Comparison
between 2 groups was done with Student’s t-test or
Wilcoxon’s rank test for continuous variables, Chi-squared
or Fischer’s exact test for categorical variables. Spearman’s
or Pearson’s correlation coefficient was obtained for corre-
lations. Receiving operating curves (ROC) analysis was used
to predict disease outcome. Uni and Multivariate Cox’s
proportional hazard regression model was used to analyze
prognostic factors. The Kaplan-Meier method with log-
rank test was used to analyze whether KL-6 levels were
associated with the disease outcome. P values of <0.05
were considered statistically significant. All statistical ana-
lyses were performed using SPSS 17 (SPSS Inc., Chicago,
IL, USA).
Results
Demographics and patients´ outcome
33 PAP patients were prospectively studied. The median
follow-up time was 510 (90–1890) days. Demographics
and disease outcome of the patients are shown in
Table 1. GM-CSF autoantibodies were detected in all 33
PAP patients. All patients experiencing disease progres-
sion (n=16) were treated with whole lung lavage (WLL).
A subgroup of patients (n=12) needed repeated WLLduring the follow-up before they stabilized. 17 patients
reached remission. At baseline, 21 patients had already
received at least one WLL before the first evaluation. Of
them, only 5 patients, all referred from other hospitals,
had received a WLL within 18 months prior to the first
evaluation.
Serum levels of KL-6
Mean serum KL-6 level was 2049±1893 U/mL (Table 1).
Men had higher KL-6 serum levels than women (2729±2311
vs 1240±656 U/mL, p=0.018). No differences in KL-6
serum levels were seen according smoking habits or fume/
dust exposure (data not shown). No correlations were seen
between KL-6 serum levels and age or BMI (data not
shown).
Patients with disease progression had higher initial
serum KL-6 levels than patients with improved/stable dis-
ease (3334±2267 vs 1084±585 U/mL, p<0.001) (Figure 1).
Initial KL-6 serum levels correlated directly with A-aDO2
(r=0.428, p=0.012), inversely with PaO2 (r=−0.35, p=0.042),
FVC (r=−0.41, p=0.02), TLC (r=−0.421, p=0.013) and
DLCO (r=−0.595, p=0.001). The strongest correlations are
shown in Figure 2. No correlations were seen between
initial serum KL-6 and initial serum LDH or GM-CSF
autoantibody (data not shown).
Changes in KL-6 serum levels over time
Correlations between changes in serum KL-6 levels
and changes in pulmonary function tests (PFTs) are
shown in Figure 3. Patients whose DLCO improved
during the follow-up period had decreasing serum KL-6
Figure 2 Correlation between initial KL-6 serum levels and pulmonary diffusing capacity. The graph shows the correlation between initial
KL-6 serum levels and (a) DLCO, (b) A-aDO2.
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production was expressed as a negative value, because
serum KL-6 concentrations were higher at the begin-
ning than at the end of the observation period.
Predictive value of baseline serum KL-6 levels for the
outcome of PAP
ROC analysis was performed to test whether baseline
serum KL-6 concentrations were predictive of disease
progression, the necessity of repeated WLL, or remis-
sion. Baseline serum KL-6 concentrations were associated
with disease progression and the necessity of repeatedFigure 3 Correlation between change in KL-6 serum levels and pulmo
between initial KL-6 serum levels and change in (a) DLCO and (b) A-aDO2WLL (Figure 4). ROC analysis for Serum LDH and GM-
CSF autoantibody did not show a predictive value for
disease progression (p=0.06 and p=0.46, respectively).
Therefore, we proceeded with the cut-off calculation
only for serum KL-6.
At the cut-off level of ≥1526 U/mL, serum KL-6 levels
yielded a sensitivity of 81% and a specificity of 94% to
predict disease progression (AUC=0.87, p=0.001). A sec-
ond cut-off was identified at ≥2157 U/mL with a sensi-
tivity of 83% and a specificity of 96% to predict the
necessity of repeated WLL (p<0.0001). PPV and NPV
and accuracy are reported in Table 2.nary diffusing capacity over time. The graph shows the correlation
over time. Shown are % values (=relative change from baseline).
Figure 4 Receiver operating characteristic curve analysis. The curves show the power of initial serum KL-6, LDH and GM-SCF for predicting
(a) disease progression, and (b) necessity of repeated WLL.
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sion, we divided all patients into two groups; the high
KL-6 group (n=14), baseline concentrations ≥1526 U/mL)
and the low KL-6 group (n=19), baseline concentrations
<1526 U/mL). The characteristics of the stratified patients
according to the KL-6 cut-off are shown in Table 3.
Plots of the incidence of disease progression and treat-
ment with repeated WLL for both groups were obtained
using the Kaplan-Meier curve (Figure 5). The incidence
of disease progression was 80% in the high KL-6 group
(n=14) and 15% in the low KL-6 group (n=19) (log-rank
test, p<0.0001). The incidence of treatment with at least
one WLL was significantly greater in the high KL-6 group
than in the low KL-6 group (73% vs 30%, p=0.028).
Predictive factors for the outcome of PAP evaluated by
the Cox proportional hazard models
We explored the predictive value of KL-6 for disease
progression. In the univariate model, baseline serum KL-6
levels ≥1526 U/mL were associated with an increased risk
of disease progression (HR, 6.28; 95% CI, 1.77-22.35;Table 2 Prognostic value of serum KL-6 for disease progressio
Se (%) Sp
KL-6 ≥1526 U/mL
Disease progression 81 9
KL-6 ≥2157 U/mL
Necessity of repeated WLL 83 9
Se=sensitivity, Sp=specificity, PPV= positive predictive value, NPV= negative predictip=0.005) (Table 4). In the multivariate model taking into
account serum markers, baseline demographics and
pulmonary function variables (Table 5), serum KL-6
levels ≥1526 U/mL remained predictive for disease pro-
gression when data were adjusted for covariates (HR,
3.84; 95% CI, 0.46-288.12; p=0.046).
We also explored the predictive value of baseline serum
KL-6 levels ≥2157 U/mL for the necessity of treatment
with repeated WLL (a subgroup of 12 patients) (HR,
20.77; 95% CI, 4.32-100.01; p<0.0001) (Table 4). In the
multivariate model baseline serum KL-6 levels ≥2157 U/mL
remained predictive for treatment with repeated WLL
when data were adjusted for covariates (HR, 9.408; 95%
CI, 0.794-111.511 p=0.008) (Table 5).
Interestingly, the combination of serum KL-6 ≥2157 U/mL
and serum LDH reached a stronger predictive value for
the treatment with repeated WLL (HR 46.45, 95% CI,
1.66-1299.26; p=0.024) than serum KL-6 alone. However,
serum LDH alone did not show a predictive value for
repeated WLL (HR 1.03, 95% CI, 0.99-1.06; p=0.068),
confirming the results of ROC analysis (see results above).n and for necessity of treatment with repeated WLL
(%) PPV NPV Accuracy
4 93 84 88
6 91 92 94
ve value.
Table 3 Characteristics of the patients stratified according to the KL-6 predictive cut-off for disease progression (N=33)
KL-6 <1526 U/mL KL-6 ≥1526 U/mL p
(N or mean ± SE) (N or mean ± SE)
Gender (M/F) 9/10 9/5 ns*
Age (yrs) 52±10 46±11 ns**
Smoking history (yes/no) 15/4 12/2 ns*
Clinical course
-PAP-related death (yes/no) 0/19 2/12 ns*
-disease progression (yes/no) 3/16 13/1 <0.0001*
Treatment (yes/no) 6/13 12/2 0.03*
-cumulative number of WLL 3.5±3 7±6.5 0.06
PaO2 (mmHg) 78±14 66±12 0.012**
A-aDO2 (mmHg) 31±12 42±14 0.023**
VC (% pred) 88±15 72±14 0.002**
FEV1 (% pred) 81±15 67±14 0.009**
TLC (% pred) 86±17 72±16 0.017**
DLCO (% pred) 70±15 42±12 <0.0001**
GM-CSF autoantibody (μg/mL) 44±19 55±13 ns**
KL-6 (U/mL) 930±352 3934±1756 <0.0001**
LDH (IU/L) 244±78 327±109 ns**
CEA (ng/mL) 5.5±3.8 7.5±6 ns**
Unless otherwise indicated, values are expressed as mean ± SD (range).
ns= not significant.
* Fischer´ s exact test.
**Student´ s t-test.
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This study showed that serum KL-6 levels correlate
with disease progression and can predict outcome in a
cohort of adult European PAP patients. At a cut-off
value of 1526 U/mL for serum KL-6, the sensitivity andFigure 5 Kaplan-Meier analysis. The graph shows the predictive value of in
repeated WLL.specificity to predict disease progression was 81% and
94%, respectively. The cut-off value of 2157 U/mL had
a sensitivity of 83% and a specificity of 96% to identify
patients that needed repeated WLL. Moreover, multi-
variate regression analysis confirmed serum KL-6 as theitial serum KL-6 levels for (a) disease progression and (b) the necessity of
Table 4 Univariate Cox proportional hazard model evaluating predictors for disease progression and the necessity of
repeated WLL
Variable Hazard ratio CI 95% p value
Disease progression
KL-6 U/mL (cont.) 1.000 1.000 1.001 0.002
KL-6 ≥1526 U/mL (binary) 6.284 1.767 22.352 0.005
Age, yrs (cont.) 0.967 0.922 1.010 0.164
Gender (female=1) 5.448 1.509 19.671 0.010
Smoking history (positive=1) 27.203 0.087 8539.00 0.260
LDH IU/L (cont.) 1.007 1.002 1.012 0.003
GM-CSF autoantibodies μg/mL (cont.) 0.993 0.968 1.020 0.617
PaO2, mmHg (cont.) 0.935 0.892 0.980 0.005
A-aDO2, mmHg (cont.) 1.067 1.020 1.115 0.010
VC, % pred. (cont.) 0.955 0.922 0.989 0.009
DLCO, % pred. (cont.) 0.948 0.909 0.989 0.012
Necessity of repeated WLL
KL-6 U/mL (cont.) 1.000 1.000 1.000 <0.001
KL-6 ≥2157 U/mL (binary) 20.776 4.316 100.015 <0.0001
Age, yrs (cont.) 0.934 0.883 0.989 0.019
Gender (female=1) 2.910 0.786 10.769 0.110
Smoking history (positive=1) 28.329 0.060 13470.548 0.288
LDH, IU/L (cont.) 1.010 1.004 1.017 0.001
GM-CSF autoantibodies, μg/mL (cont.) 0.996 0.967 1.025 0.767
PaO2, mmHg (cont.) 0.923 0.875 0.975 0.004
A-aDO2, mmHg (cont.) 1.095 1.032 1.162 0.003
VC, % pred. (cont.) 0.940 0.906 0.975 0.001
DLCO, % pred. (cont.) 0.935 0.892 0.980 0.005
Definition of abbreviation: CI; confidence interval.
Table 5 Multivariate Cox proportional hazard model evaluating predictors for disease progression and the necessity of
repeated WLL
Variable Hazard ratio* CI 95% p value
Disease progression
KL-6, U/mL (cont.) 0.999 0.998 1.000 0.090
KL-6 ≥1526, U/mL (binary) 3.844 0.460 288.120 0.046
Gender (female=1) (binary) 18.030 2.378 136.696 0.051
Necessity of repeated WLL
KL-6, U/mL (cont.) 1.000 1.000 1.001 0.196
PaO2, mmHg (cont.) 0.897 0.579 0.969 0.028
KL-6 ≥2157, U/mL (binary) 9.408 0.794 111.511 0.008
PaO2, mmHg (cont.) 0.97 0.93 1.00 0.038
LDH, IU/L (cont) 46.449 1.661 1299,262 0.024
Definition of abbreviation: CI; confidence interval.
* Calculated by stepwise conditional LR method. All significant predicting factors in the univariate analysis were included in the multivariate model. Only the
factors that influence the model (adjusting factors) are reported in the Table.
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repeated WLL.
It is known that serum KL-6 levels are extremely ele-
vated in PAP patients, with mean values being much
higher than those in any other ILD [3,12,20,23,33,34]. In
our PAP cohort the mean serum KL-6 level (mean, 2049
U/mL) was considerably lower than reported by Inoue
et al. in Japanese PAP patients (mean, 6067 U/mL) [3], but
similar to the value observed in Chinese PAP patients
(mean, 3127 U/mL) [11]. The prevalence of a particular
genetic variant in the MUC1 gene may influence the
serum levels of KL-6, as previously reported in a Dutch
cohort [34].
We confirmed published data on the association of
serum KL-6 with lung function tests and blood gas analyses
[3,10,11]. Patients with progressive disease had higher levels
of serum KL-6, as described by Inoue et al. [3]; the correl-
ation with DLCO and PaO2 was confirmed in our pa-
tients [10,11].
Whereas a serum KL-6 level ≥1526 U/mL predicted
disease progression with a sensitivity of 81% and a speci-
ficity of 94% neither serum LDH or serum GM-CSF
autoantibody did show a predictive value for disease pro-
gression. The poor correlation with severity of disease
and the weak power of GM-CSF autoantibodies to pre-
dict PAP outcome are known [3,10,14,30,35,36]. The
better predictive value of serum KL-6 in comparison to
serum GM-CSF autoantibody may be explained by the
origin and the metabolism of KL-6. Whereas GM-CSF
autoantibodies are produced systemically by B-cell derived
plasmocytes, KL-6 is locally produced by pneumocytes
type II and then accumulates in the proteinaceous mater-
ial of PAP patients [9,24]. KL-6 is consistently present in
the epithelial lining fluid in PAP and various ILDs [24,37].
The mechanisms of increase in serum KL-6 level are
thought to be an increase in KL-6 production and/or an
increased permeability of the air– blood barrier in the
affected lungs [13,20].
The patients with serum KL-6 levels ≥1526 U/mL had
worse lung function tests than patients with lower levels,
but the serum levels of LDH, GM-CSF autoantibodies
and CEA did not differ significantly between the two
groups. The incidence of disease progression was 80% in
patients with higher serum KL-6 levels versus 15% in
those with lower levels. The multivariate analysis showed
that a serum KL-6 level ≥1526 U/mL, but not KL-6 as
continuous variable, was associated with a 3.8 hazard of
disease progression even after adjusting for covariates.
The threshold of 1526 U/mL for serum KL-6 established
by this study might be different in other cohorts. How-
ever, this does not impact our finding that patients
with high KL-6 serum concentrations have a higher
risk of disease progression than patients with lower
serum levels.From previous studies it is known that 5 to 10% of
PAP patients can reach a spontaneous remission [2,3,30],
75 to 90% after treatment with at least one WLL. There
is a consistent subgroup of patients that need repeated
WLL, above all smokers. Therefore, we investigated
whether this subgroup of 12 patients can be identified
at baseline. We found that a cut-off value of 2157 U/mL
for initial serum KL-6 had an accuracy of 94% in identi-
fying these patients. The high specificity of this cut-off
(96%) may be helpful to identify responders to WLL. In
order to test the possible role of KL-6 as a predictor for
the need of repeated WLL, we performed uni- and multi-
variate analysis adjusting the model for covariates (age, gen-
der and smoking habits). KL-6 at the cut-off 2157 U/mL
was the strongest predictor for the need of repeated WLL,
with a hazard ratio of 9.4 in the multivariate analysis.
According to our findings, the predictive power of
serum KL-6 is high. Both disease progression and the
need of repeated WLL are affected by patient age, gen-
der, smoking history, and baseline physiology, but hazard
proportional ratios for these parameters are below 2.0
and often not significant. In recent years, there was
increasing interest to define accurate predictors of out-
come in PAP. Up to now, the best predictors of survival
have been PFTs or composite (clinical-physiological) pa-
rameters, like the disease severity score DSS [3,30,38].
This is the first study to demonstrate that a single serum
biomarker at baseline can predict outcome in PAP.
There are several limitations of this study that need to
be addressed. First, we did not check for the mucin-1
568 A/G polymorphism that is known to influence KL-6
serum levels [20,34]. In fact, even if higher levels of
serum KL-6 have been reported in healthy Europeans
[33,34] in comparison to Japanese, our PAP patients had
lower levels of serum KL-6 than the Japanese, also with
advanced disease. A validation study is needed to clarify
this point. Second, we could not find a predictive value
of serum KL-6 for mortality because the death rate was
low in our cohort during the observational period.
Third, baseline data of our patients were not absolute
baseline data at time of diagnosis, but data obtained at
the time of first blood sampling for serum KL-6, making
the cohort at baseline remarkably heterogeneous.
In conclusion, we were able to demonstrate that KL-6
is a predictive serum biomarker for the outcome of PAP.
This may be of benefit in the clinical management of
patients with PAP. Although our data are promising, a
multicentre validation is necessary to determine whether
serum KL-6 should be routinely used as a prognostic bio-
marker in PAP.
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